Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
today announced the publication of results from
C-EDGE
CO-STAR
. C-EDGE CO-STAR is a Phase 3 trial evaluating the
use of ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets in
patients with chronic hepatitis C (HCV) genotype (GT) 1, GT4 and GT6
infection receiving opioid agonist therapy (OAT) (methadone and
buprenorphine), commonly used to treat opioid addiction.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orSarra Herzog, 201-669-6570orInvestor:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more